Value
7.6/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 8.3 |
| Fwd P/E | 5.2 |
| PEG | 10.0 |
| Analyst target | 6.0 |
- ▸Forward P/E: 24.3x
- ▸PEG: 0.18
- ▸Attractively valued
CTKB · Why this verdict
Why Cytek Biosciences (CTKB) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.4/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Cytek is FCF-positive but with thin margins (3% FCF margin, 1.1% FCF yield), leaving limited cushion if revenue growth of 4.1% slows further. Quality breakdown | FCF margin expands above 5% within the next fiscal year, showing improving cash-flow durability. | →Stable |
| CounterThin FCF margins combined with a lack of competitive moat mean any competitive or pricing pressure could quickly turn the company cash-flow negative. | ||
Cytek's setup is classified as momentum continuation, with RSI at 67 and a bullish MACD crossover, trading above its 200-day moving average with rising on-balance volume. Chart pattern detection | Price continues trending higher, staying above the 200-day moving average through the next 2 quarters. | →Stable |
| CounterAn RSI of 67 is already approaching overbought territory, and the quality score of 3.2 sits below the engine's 4.0 floor, suggesting the continuation setup lacks fundamental support. | ||
Cytek trades at a PEG ratio of just 0.18 despite a forward P/E of 24.2x, suggesting the earnings-growth-adjusted valuation is attractive. Valuation breakdown | The PEG ratio stays below 0.4 over the next 12 months if the growth-adjusted value case holds. | →Stable |
| CounterThe company has missed consensus EPS estimates in 2 of its last 4 quarters with an average surprise of -521%, meaning the earnings growth embedded in the PEG calculation may be unreliable. | ||
Cytek's quality score of 3.2 sits below the engine's 4.0 minimum floor, triggering the exit recommendation despite a favorable technical setup. Bear case | Quality score rises above 4.0 within 2 quarters if fundamentals meaningfully strengthen. | →Stable |
| CounterThin FCF margins and no competitive moat suggest the quality shortfall reflects structural weakness rather than a temporary dip. | ||
Cytek's asymmetry ratio of 0.35 sits well below the 1.5 threshold the engine requires for an attractive risk/reward, with only 5.3% upside against 15.0% downside. Reward-to-risk math | The asymmetry ratio rises above 1.0 within 2 quarters as either upside expands or downside risk narrows. | →Stable |
| CounterA history of large negative earnings surprises suggests downside risk could realistically expand further rather than narrow. | ||
Cytek is FCF-positive but with thin margins (3% FCF margin, 1.1% FCF yield), leaving limited cushion if revenue growth of 4.1% slows further.
→StableQuality breakdown
- Expectation
- FCF margin expands above 5% within the next fiscal year, showing improving cash-flow durability.
CounterThin FCF margins combined with a lack of competitive moat mean any competitive or pricing pressure could quickly turn the company cash-flow negative.
Cytek's setup is classified as momentum continuation, with RSI at 67 and a bullish MACD crossover, trading above its 200-day moving average with rising on-balance volume.
→StableChart pattern detection
- Expectation
- Price continues trending higher, staying above the 200-day moving average through the next 2 quarters.
CounterAn RSI of 67 is already approaching overbought territory, and the quality score of 3.2 sits below the engine's 4.0 floor, suggesting the continuation setup lacks fundamental support.
Cytek trades at a PEG ratio of just 0.18 despite a forward P/E of 24.2x, suggesting the earnings-growth-adjusted valuation is attractive.
→StableValuation breakdown
- Expectation
- The PEG ratio stays below 0.4 over the next 12 months if the growth-adjusted value case holds.
CounterThe company has missed consensus EPS estimates in 2 of its last 4 quarters with an average surprise of -521%, meaning the earnings growth embedded in the PEG calculation may be unreliable.
Cytek's quality score of 3.2 sits below the engine's 4.0 minimum floor, triggering the exit recommendation despite a favorable technical setup.
→StableBear case
- Expectation
- Quality score rises above 4.0 within 2 quarters if fundamentals meaningfully strengthen.
CounterThin FCF margins and no competitive moat suggest the quality shortfall reflects structural weakness rather than a temporary dip.
Cytek's asymmetry ratio of 0.35 sits well below the 1.5 threshold the engine requires for an attractive risk/reward, with only 5.3% upside against 15.0% downside.
→StableReward-to-risk math
- Expectation
- The asymmetry ratio rises above 1.0 within 2 quarters as either upside expands or downside risk narrows.
CounterA history of large negative earnings surprises suggests downside risk could realistically expand further rather than narrow.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Cytek Biosciences shows a bullish momentum-continuation setup and an attractive PEG ratio, but a sub-floor quality score, thin free-cash-flow margins, a history of large negative earnings surprises, and weak asymmetry keep the engine's stance at exit.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 6.3 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 8.3 |
| FCF quality | 3.6 |
| Moat | 6.6 |
| Piotroski F | 6.7 |
- ▸FCF-positive but moderate margins (FCF margin 3%, FCF yield 1.1%)
Growth
7.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 4.1 |
| EPS growth | 10.0 |
Momentum
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 7.3 |
| OBV | 4.8 |
| MA position | 7.2 |
| Volume | 0.0 |
- ▸Below 200-MA but MA still rising (+0.6%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 8.5 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 30%
Insider
5.0/10data confidence 50%Peer rank
4.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.6 |
| quality rank | 2.0 |
| growth rank | 3.5 |
- ▸Conservative debt levels
Technical
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.5 |
| support resistance | 3.4 |
| 52w position | 4.2 |
Risk (lower is worse)
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.5 |
| days to cover | 4.2 |
| volatility | 0.0 |
| max pain risk | 3.0 |
| beta | 6.3 |
| debt equity | 9.7 |
- ▸Above max pain $2
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 0B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:4.8>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:30d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.7<1.5@spot
Warning (1)
- MOMENTUM:4.8<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
0.67
Upside
+10.1%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 59 mid-range, Bollinger mid-band
EdgeInst Constrain — Small cap ($0.6B) below institutional reach
SuitabilityAggressive — MCap $0.6B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 7.6 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:0.7<1.5@spot.
The strongest dimensions are Value at 7.6, Growth at 7.0, and Sentiment at 6.1; the weakest are Catalyst at 2.5, Quality at 3.5, and Technical at 3.7. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 0.67 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Momentum Continuation Setup
Trip ifThe stock closes below its 200-day moving average, or RSI falls below 40, ending the momentum-continuation read.
- P2Peg Valuation Cheapness
Trip ifCytek misses consensus EPS estimates by more than 10% for a third consecutive quarter at its next earnings report.
- P3Quality Floor Exit Signal
Trip ifThe quality score stays below 2.5 at the next quarterly refresh, confirming the exit signal remains valid.
- P4Negative Asymmetry Risk Reward
Trip ifThe asymmetry ratio stays below 0.5 for 2 consecutive quarterly refreshes.
- P5Thin Fcf Margin Risk
Trip ifFCF margin falls below 0% at the next annual report, turning cash-flow negative.